Highlights

• Sun Pharmaceutical shares climbed 1.09% and touched a fresh 52-week high.
• The stock delivered over 174% returns during the last five-year period.
• Market capitalisation crossed INR 4.55 lakh crore during Monday’s trading session.

Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) shares gained 1.17% on May 18, 2026, reaching INR 1900.10 during intraday trading on the NSE. The stock touched a fresh 52-week high of INR 1,899 during the session. The stock opened at INR 1,878.20, which was also the previous closing level. During the trading session, the stock moved between an intraday low of INR 1,865 and the record high level.

Trading activity remained active with 14.71 lakh shares changing hands on the exchange. Traded value during the session stood at approximately INR 277.29 crore. The company’s total market capitalisation was reported at INR 4,55,201.83 crore, while free float market capitalisation stood at INR 2,00,345.52 crore.

Source: TradingView

Stock Outperforms NIFTY 50 Across Multiple Periods

Sun Pharmaceutical outperformed the NIFTY 50 index across several timeframes. The stock delivered returns of 1.32% in one week and 13.25% over one month, while the benchmark index recorded declines during the same periods.

Year-to-date returns stood at 10.25%, compared with a 9.71% decline in the NIFTY 50 index. The stock generated returns of 9.37% over one year and 104.11% over the last three years. Over a five-year period, Sun Pharmaceutical shares gained 174.68%.

Volatility and Trading Indicators

The stock recorded daily volatility of 1.34%, while annualised volatility stood at 25.60%.

Sun Pharmaceutical’s applicable margin rate was reported at 12.50%, while deliverable quantity as a percentage of traded quantity stood at 59.89%.

The stock traded without any price band restrictions during the session. The upper reference band stood at INR 2,066, while the lower reference level was INR 1,690.40.

Global Pharmaceutical Manufacturing Operations

Sun Pharmaceutical Industries operates in the manufacturing, development, and marketing of branded and generic formulations along with active pharmaceutical ingredients (APIs).

The company and its subsidiaries maintain manufacturing facilities across several countries, while trading and related business activities extend to global markets.

Sun Pharmaceutical is also identified as India’s largest pharmaceutical company based on market presence.

Source: Company filing

Key Risks

• Regulatory observations may affect pharmaceutical manufacturing operations globally.
• Pricing pressure in generic medicines could impact profitability margins.
• Currency fluctuations may influence overseas revenue and earnings performance.
• Dependence on regulated markets may increase compliance-related costs.

Summary

Sun Pharmaceutical Industries (NSE:SUNPHARMA) shares gained more than 1% on May 18, 2026, touching a fresh 52-week high during intraday trading on the NSE. The stock continued outperforming the NIFTY 50 index across multiple timeframes, including five-year gains exceeding 174%. The pharmaceutical company operates globally across branded formulations, generic medicines, and active pharmaceutical ingredient manufacturing businesses.

FAQs

Q: Why did Sun Pharmaceutical shares rise on May 18, 2026?
A: The stock gained during trading and touched a fresh 52-week high on the NSE.

Q: What were Sun Pharmaceutical’s five-year stock returns?
A: The stock delivered returns of 174.68% during the last five-year period.

Q: What business does Sun Pharmaceutical Industries operate in?
A: The company manufactures branded formulations, generic medicines, and active pharmaceutical ingredients globally.